Pomadoamine is FDA approved as the first treatment for AIDS-related Caposi sarcoma in more than 20 years
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Bristol Myers Squibb has announced that its Pomalyste (pomalidomide, Pomadomide) has been approved by the U.SFood and Drug Administration (FDA) to treat patients with Kaposi sarcoma who develop resistance to highly active antiretroviral therapy (HAART) that are resistant or HIV-negativethis accelerated approval is based on the overall remission rate observed by Pomalyst in the 1/2 Open Label Single Arm Clinical Trial (12-C-0047), which has previously been named Breakthrough Therapy and Orphan DrugCaposi sarcoma is a rare form of cancer that usually manifests itself as a skin lesions but can also develop to other parts of the body, including the lungs, lymph nodes and digestive systemIn the United States, the disease develops at a rate of about six per million people per year and mainly affects people with low immune functionAs an oral drug, Pomalyst became the first treatment option for patients with Kaposi sarcoma in more than 20 yearsDiane McDowell, vice president of global medical affairs at Bristol Myers Squibb Hematology, said: 'Patients with Caposi asarcoma have had little treatment options for the past two decadesWe are pleased that Pomalyst is able to provide patients with this much-needed oral treatment option in this rare area of diseaseThe black-box warningprescription information emphasizes that Pomalyst may cause fetal harm and is prohibited in pregnant women
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
